Skip to main content
Premium Trial:

Request an Annual Quote

Now Most UK Cases

Sharon Peacock, the director of COVID-19 Genomics UK, says the B.1.1.7 variant of SARS-CoV-2 has taken over there, Reuters reports.

Health officials in the UK sounded the alert about the B.1.1.7 SARS-CoV-2 variant in December, and subsequent studies have suggested that the B.1.1.7 variant — which was first detected in the UK in September 2020, according to Reuters — is about 50 percent more transmissible than previous viral variants and a recent study has suggested it may also be more deadly.

In an online briefing for the Royal Society of Medicine, Peacock said the B.1.1.7 variant is now widespread in the UK, according to Reuters. "We now know that it has spread across the UK and causes nearly all of the cases of COVID-19 — about 98 percent," she said. "It appears to be the case that the other variants are not getting a foothold in this country."

Reuters notes that the B.1.1.7 variant has since been uncovered in countries around the world, including the US. Peacock added that she expects the variant will expand quickly wherever it is found, according to Reuters.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.